MENU Our response to COVID-19 As we all take steps to address COVID-19, we would like to provide an update on our response strategy at Akcea Therapeutics. We are well positioned to address challenges related to COVID-19 and to continue to advance our clinical programs as well as our commercial strategies. Our outstanding team rapidly adapted to working remotely and we are monitoring daily to ensure we have all necessary plans in place for mitigating potential disruptions in our daily operations, including clinical programs and ongoing drug supply and nursing support for the patients and clinicians who rely on us. Our COVID-19 Task Force is proactively assessing, monitoring, and responding to international developments related to the pandemic and is implementing risk-mitigation plans on an ongoing basis to minimize impact on our clinical trials, supply chain, and business operations. We: monitor conditions on the ground for our patients and staff daily, in particular through our global Akcea Connect program, which is setting the standard for patient care in rare diseases; monitor our supply chain daily; continue to actively support our partnerships; are in a strong financial position and are working to maximize opportunities related to our commercially available products. Our mission to advance research to develop new treatments for rare diseases, combined with our strong business operations, reinforces our continuing commitment to the patient populations we serve, including the hereditary transthyretin-mediated amyloidosis (ATTR) and familial chylomicronemia syndrome (FCS) communities. We are fortunate to meet regularly with many patients and caregivers, and know firsthand the challenges they face—made even more difficult by the COVID-19 outbreak. Our commitment to patients, caregivers, and clinicians on the front lines in managing these diseases is unwavering and our goal is to keep existing patients on therapy safely and to support the initiation of new patients onto therapy. To date, COVID-19 has not impacted our ability to fulfill patient demand for our 2 marketed products. Both medicines are administered through self-injection in the comfort and safety of a patient’s home, and they do not require a patient to go to an infusion center or hospital for treatment. Thank you for your continuing interest in our work at Akcea. In addition to our monitoring, we take guidance from the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), and will provide ongoing updates on our strategies related to COVID-19. Careers | Privacy Policy | Terms of Use | Contact | Compliance Governance Documents Akcea Therapeutics 22 Boston Wharf Road, 9th Floor, Boston MA 02210 (617) 207-0202 info@akceatx.com © 2021, all rights reserved Akcea Therapeutics has been acquired by Ionis Pharmaceuticals. For continued news and information about Akcea Therapeutics, please visit ionispharma.com. You are being redirected, please wait. If you have not been redirected in 30 seconds, please click the button below. Go to ionispharma.com